Senolytic Therapies — Meaningful Human Healthspan Extension

Surrogate-to-clinical translation gap. Senolytic therapies demonstrably reduce surrogate markers of senescence (p16, SASP cytokines, senescent cell counts) in humans. What remains undemonstrated is that these surrogate reductions produce clinically meaningful improvements in healthspan outcomes. The translation gap between surrogate biomarkers and clinical endpoints is a well-characterised problem in drug development — many interventions that improve surrogate markers fail to demonstrate clinical benefit. For senolytics, this gap is compounded by the long timescales required for clinical endpoint measurement. The resistance mechanism is structural: surrogate evidence accumulates on timescales of months; clinical evidence requires years to decades.

Biological variability and patient heterogeneity. Senescent cell burden, SASP composition, and tissue-specific effects vary substantially across individuals, ages, and disease states. The optimal senolytic drug, dose, frequency, and target population for healthspan extension in healthy humans has not been identified. Clinical trials in specific disease populations (osteoarthritis, diabetic kidney disease, pulmonary fibrosis) may not generalise to healthy aging prevention. The heterogeneity means that a null result in one population and indication does not cleanly contest the claim for other populations and indications — but it also means the claim requires evidence across multiple settings before it can be confirmed.

"Meaningfully extend" lacks an agreed threshold. The claim requires meaningful extension of healthy lifespan, but no agreed clinical threshold defines what "meaningful" means. Is one year of additional healthy function meaningful? Five years? A 10% reduction in age-related disease incidence? The FDA has not approved any intervention for the indication of "aging" or "healthspan extension" — the regulatory framework does not currently accommodate such claims, meaning clinical trials cannot be powered against a standard threshold. This is a lexical and regulatory bottleneck of the same type as FR-AI-0004 ("previously unseen") and FR-AI-0006 ("same mechanism") — the fourth such bottleneck in the corpus. Without an agreed threshold, the claim cannot transition to any resolved state regardless of evidence accumulation.

FDA "geroscience" indication and validated biomarker panel. Two developments would materially advance this record: first, FDA regulatory framework for aging as an indication (currently under discussion through the TAME trial — Targeting Aging with Metformin — and geroscience initiatives), which would create a governed clinical endpoint for healthspan extension; second, a validated biomarker panel that correlates with subsequent healthspan outcomes, providing a surrogate endpoint that is accepted as predictive. Both developments are in progress. If achieved, they would resolve BN-001 by providing an agreed threshold and make Phase III trials of senolytics tractable on five-to-ten year rather than twenty-to-thirty year timescales.